Secondary cancer after meningioma diagnosis: an Israeli national study.
Early detection
Meningioma
Risk factors
Secondary primary cancer
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
04
2022
accepted:
29
06
2022
pubmed:
25
7
2022
medline:
2
9
2022
entrez:
24
7
2022
Statut:
ppublish
Résumé
There are limited data on whether primary diagnosis of meningioma may be associated with development of secondary primary cancer (SPC). All meningioma cases (ICD-O-3 morphology codes 9530/0-9539/3) diagnosed in Jewish Israelis ≥ 20 years 1990 through 2015 registered in the Israel National Cancer Registry (INCR) were retrieved. All subsequent cancers occurring more than 6 months after meningioma diagnosis were identified. Risk of secondary cancer (SPC) was compared to cancer risk in the general population through the calculation of standardized incidence ratios (SIRs) and excess absolute risks (EARs). SIRs were stratified by type of second cancer, sex, and age group. Cox regression models were used to estimate hazard ratios of developing SPC. Overall, 8044 meningioma cases were identified: mean age at diagnosis was 64.0 ± 14.1 years. Of these, 927 (11.5%) were diagnosed with SPC (SIR 1.6, 95% CI 1.5-1.7). SPC risk was elevated in men (SIR 1.6, 95% CI 1.5-1.9) and women (SIR 1.6, 95% CI 1.5-1.8) diagnosed with meningioma in univariable analyses. Cancers most commonly encountered in the studied population were breast (17.6%), colorectal (13.4%), lung (8.1%), prostate (5%), and bladder (4.6%) cancer. In multivariable analyses, 10+ year increment in age at meningioma diagnosis was significantly associated with higher risk for SPC in individuals diagnosed with meningioma between 20 and 64 years, with an inverse association in the older age group (65+ years). Meningioma diagnosis is associated with an increased risk for developing secondary cancers. This risk should be discussed with patients treated for meningioma.
Sections du résumé
BACKGROUND
BACKGROUND
There are limited data on whether primary diagnosis of meningioma may be associated with development of secondary primary cancer (SPC).
METHODS
METHODS
All meningioma cases (ICD-O-3 morphology codes 9530/0-9539/3) diagnosed in Jewish Israelis ≥ 20 years 1990 through 2015 registered in the Israel National Cancer Registry (INCR) were retrieved. All subsequent cancers occurring more than 6 months after meningioma diagnosis were identified. Risk of secondary cancer (SPC) was compared to cancer risk in the general population through the calculation of standardized incidence ratios (SIRs) and excess absolute risks (EARs). SIRs were stratified by type of second cancer, sex, and age group. Cox regression models were used to estimate hazard ratios of developing SPC.
RESULTS
RESULTS
Overall, 8044 meningioma cases were identified: mean age at diagnosis was 64.0 ± 14.1 years. Of these, 927 (11.5%) were diagnosed with SPC (SIR 1.6, 95% CI 1.5-1.7). SPC risk was elevated in men (SIR 1.6, 95% CI 1.5-1.9) and women (SIR 1.6, 95% CI 1.5-1.8) diagnosed with meningioma in univariable analyses. Cancers most commonly encountered in the studied population were breast (17.6%), colorectal (13.4%), lung (8.1%), prostate (5%), and bladder (4.6%) cancer. In multivariable analyses, 10+ year increment in age at meningioma diagnosis was significantly associated with higher risk for SPC in individuals diagnosed with meningioma between 20 and 64 years, with an inverse association in the older age group (65+ years).
CONCLUSIONS
CONCLUSIONS
Meningioma diagnosis is associated with an increased risk for developing secondary cancers. This risk should be discussed with patients treated for meningioma.
Identifiants
pubmed: 35871439
doi: 10.1007/s10552-022-01609-3
pii: 10.1007/s10552-022-01609-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1277-1284Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99(3):307–314. https://doi.org/10.1007/s11060-010-0386-3
doi: 10.1007/s11060-010-0386-3
pubmed: 20821343
pmcid: 2945461
Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S (2020) An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol 39(4):643–665. https://doi.org/10.1007/s00401-019-02029-5
doi: 10.1007/s00401-019-02029-5
Kok JL, Teepen JC, van Leeuwen FE et al (2019) Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol 21(3):392–403. https://doi.org/10.1093/neuonc/noy124
doi: 10.1093/neuonc/noy124
pubmed: 30099534
Brenner AV, Sugiyama H, Preston DL et al (2020) Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958–2009. Eur J Epidemiol 35(6):591–600. https://doi.org/10.1007/s10654-019-00599-y
doi: 10.1007/s10654-019-00599-y
pubmed: 31982981
pmcid: 7329623
Felicetti F, Fortunati N, Garbossa D et al (2015) Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience. J Cancer Res Clin Oncol 141(7):1277–1282. https://doi.org/10.1007/s00432-015-1920-7
doi: 10.1007/s00432-015-1920-7
pubmed: 25609074
Helseth A, Mørk SJ, Glattre E (1989) Neoplasms of the central nervous system in Norway. V. Meningioma and cancer of other sites. An analysis of the occurrence of multiple primary neoplasms in meningioma patients in Norway from (1955) through 1986. APMIS 97(8):738–744
Custer BS, Koepsell TD, Mueller BA (2002) The association between breast carcinoma and meningioma in women. Cancer 94(6):1626–1635. https://doi.org/10.1002/cncr.10410
doi: 10.1002/cncr.10410
pubmed: 11920521
Inskip PD (2003) Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer. Cancer 98(3):562–570. https://doi.org/10.1002/cncr.11554
doi: 10.1002/cncr.11554
pubmed: 12879474
Strodtbeck K, Sloan A, Rogers L et al (2013) Risk of subsequent cancer following a primary CNS tumor. J Neurooncol 112(2):285–295. https://doi.org/10.1007/s11060-013-1063-0
doi: 10.1007/s11060-013-1063-0
pubmed: 23392847
pmcid: 3777246
Bao X, Cao L, Piao H, Xie L (2014) Treatment-related secondary cancer in malignant meningiomas: a population-based study. J Cancer Res Clin Oncol 140(4):583–588. https://doi.org/10.1007/s00432-013-1493-2
doi: 10.1007/s00432-013-1493-2
pubmed: 24509624
Davis F, Tavelin B, Grutsch J, Malmer B (2007) Second primary tumors following a diagnosis of meningioma in Sweden, 1958–1997. Neuroepidemiology 29(1–2):101–106. https://doi.org/10.1159/000109823
doi: 10.1159/000109823
pubmed: 17940341
Moore E, Silverman BG, Fishler Y et al (2021) An Assessment of the Completeness and Timeliness of the Israel National Cancer Registry. Isr Med Assoc J 23(1):23–27
pubmed: 33443338
https://www.health.gov.il/English/MinistryUnits/HealthDivision/Icdc/Icr/Pages/default.aspx . Accessed 15 May 2022
Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Counsel 21:151–161. https://doi.org/10.1007/s10897-011-9462-x
doi: 10.1007/s10897-011-9462-x
Goutagny S, Kalamarides M (2010) Meningiomas and neurofibromatosis. J Neurooncol 99(3):341–347. https://doi.org/10.1007/s11060-010-0339-x
doi: 10.1007/s11060-010-0339-x
pubmed: 20714782
https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=637 . Accessed 15 May 2022
Yamanaka R, Hayano A, Kanayama T (2017) Radiation-induced meningiomas: an exhaustive review of the literature. World Neurosurg 97:635-644.e8. https://doi.org/10.1016/j.wneu.2016.09.094
doi: 10.1016/j.wneu.2016.09.094
pubmed: 27713063
Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M (2011) Family and personal medical history and risk of meningioma. J Neurosurg 115(6):1072–1077. https://doi.org/10.3171/2011.6.JNS11129
doi: 10.3171/2011.6.JNS11129
pubmed: 21780859
pmcid: 3241000
Sadetzki S, Modan B, Chetrit A, Freedman L (2000) An iatrogenic epidemic of benign meningioma. Am J Epidemiol 151(3):266–272. https://doi.org/10.1093/oxfordjournals.aje.a010202
doi: 10.1093/oxfordjournals.aje.a010202
pubmed: 10670551
Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I (2005) Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for Tinea capitis. Radiat Res 163(4):424–432. https://doi.org/10.1667/rr3329.Erratum.In:RadiatRes.2005Aug;164(2):234
doi: 10.1667/rr3329.Erratum.In:RadiatRes.2005Aug;164(2):234
pubmed: 15799699
Hemminki K, Li X (2003) Familial risks in nervous system tumors. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1137–1142
pubmed: 14652272
Barchana M, Liphshitz I (2013) High incidence of benign brain meningiomas among Iranian-born Jews in Israel may be linked to both hereditary and environmental factors. Asian Pac J Cancer Prev 14(10):6049–6053. https://doi.org/10.7314/apjcp.2013.14.10.6049
doi: 10.7314/apjcp.2013.14.10.6049
pubmed: 24289623